Drugs that contain Lasmiditan Succinate

1. List of Reyvow drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7423050 ELI LILLY AND CO Pyridinoylpiperidines as 5-HT1F agonists
Apr, 2025

(2 years from now)

US11053214 ELI LILLY AND CO Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
Dec, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8748459 ELI LILLY AND CO Pyridinoylpiperidines as 5-HT1F agonists
Mar, 2023

(6 days from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 31, 2025

NCE-1 date: 2024-02-01

Market Authorisation Date: 31 January, 2020

Treatment: Acute treatment of migraine

Dosage: TABLET;ORAL

More Information on Dosage

REYVOW family patents

11

United States

4

China

4

Japan

3

Korea, Republic of

3

Canada

2

Portugal

2

Spain

2

Brazil

2

Croatia

2

Costa Rica

2

New Zealand

2

Mexico

2

Peru

2

Taiwan, Province of China

2

EA

2

South Africa

2

Ukraine

2

Poland

2

Australia

2

Ecuador

2

Denmark

2

European Union

1

Germany

1

Moldova, Republic of

1

Malaysia

1

Jordan

1

Colombia

1

Dominican Republic

1

Egypt

1

Norway

1

Philippines

1

Austria

1

Argentina

1

Morocco

1

Hong Kong

1

Tunisia

1

Lithuania

1

Hungary

1

Slovenia

1

Israel

1

Chile

1

RS

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in